The expression of these two genes has been reported in well and dedifferentiated liposarcoma.24 CDK4 inhibitors, such as palbociclib, are FDA approved for breast cancer therapies,25 and MDM2 inhibitors, including nutlin-3, also display exciting prospects.26 Interestingly, we found that the HDAC gene family was also extensively amplified in 73% of the samples (HDAC1 in 2/11 patients, HDAC2 in 4/11, HDAC3 in 1/11, HDAC4 in 1/11, HDAC5 in 1/11, HDAC7 in 3/11, HDAC9 in 6/11 and HDAC10 in 2/11 patients; figure 1B). The gene discussed is HDAC5; the disease is breast cancer.